NAD+: What the Research Says
A coenzyme every cell in your body runs on — and a field where the preclinical science is rich, the human trial data is thin, and the marketing often outruns both.
What is NAD+?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It was first characterized in 1906, and its role in cellular metabolism has been a central topic in biochemistry for more than a century. NAD+ shuttles electrons in redox reactions across the mitochondria, powering ATP production.
Beyond energy metabolism, NAD+ is also consumed by a class of signaling enzymes — sirtuins, PARPs, CD38, and SARM1 — that regulate DNA repair, inflammation, circadian rhythm, and cellular stress responses. That multi-role profile is why NAD+ has become a major focus of aging biology over the past two decades.
Tissue NAD+ levels — in skin, muscle, and other tissues — decline with age in animal and human studies (Massudi et al., PLOS One, 2012; Gomes et al., Cell, 2013). Whole blood NAD+ decline in humans is less consistent across studies and appears to differ by sex and age band (Zhou et al., Frontiers in Endocrinology, 2022) — an important nuance when interpreting plasma NAD+ as an aging biomarker. The tissue observation, combined with a growing preclinical literature on NAD+ repletion in aged model organisms, is the foundation of current therapeutic interest.
How it works (proposed mechanisms)
Electron transport & ATP
NAD+ cycles between its oxidized (NAD+) and reduced (NADH) forms, carrying electrons through the mitochondrial electron transport chain. This cycling is a rate-limiting step in oxidative phosphorylation, the dominant source of cellular ATP. Declines in cellular NAD+ availability are associated with reduced mitochondrial function in aged tissues (Gomes et al., Cell, 2013).
SIRT1–SIRT7 signaling
Sirtuins are NAD+-dependent deacetylases implicated in metabolic regulation, DNA repair, and longevity pathways. Because sirtuins consume NAD+ as a substrate, their activity scales with NAD+ availability. Work from the Sinclair lab (Harvard) and others has linked NAD+-sirtuin signaling to mitochondrial biogenesis and cellular stress resistance in animal models.
PARP-dependent repair
Poly(ADP-ribose) polymerases (PARPs) use NAD+ to synthesize poly-ADP-ribose chains, which are central to the detection and repair of single-strand DNA breaks. PARP activation in response to DNA damage can rapidly deplete cellular NAD+ pools, linking genomic stress to broader NAD+ bioavailability.
CD38 and tissue crosstalk
CD38 is a major NAD+-consuming enzyme whose expression increases with age, contributing to the age-related decline in tissue NAD+ (Camacho-Pereira et al., Cell Metabolism, 2016). CD38 biology links NAD+ availability to immune and inflammatory signaling pathways.
A practical caveat: intact NAD+ is a large, charged molecule that does not readily cross cell membranes. Most researchers believe that injected or infused NAD+ is broken down extracellularly into precursors (nicotinamide, NMN) that are then transported into cells and resynthesized to NAD+. This pharmacokinetic detail is debated but consequential — it means direct NAD+ delivery may function mechanistically similar to precursor administration.
What the research suggests
Honest framing: the NAD+ preclinical literature (mouse and cell studies) is large and rapidly growing. The human trial literature is still small, and most published human studies have used NAD+ precursors (NR, NMN) rather than injectable NAD+ itself. Findings from precursor trials are suggestive but not definitive.
NAD+ and aging biology (preclinical)
Gomes et al. (Cell, 2013) showed that raising cellular NAD+ in aged mice restored mitochondrial function in skeletal muscle. Subsequent work across multiple labs has demonstrated improvements in insulin sensitivity, exercise endurance, and markers of cellular stress in rodent models. Translating these findings to humans is the open question.
Human NR/NMN precursor studies
Martens et al. (Nature Communications, 2018) found that oral nicotinamide riboside (NR) reliably raised blood NAD+ metabolite levels in healthy older adults. Conze, Brenner & Kruger (Scientific Reports, 2019) confirmed the biomarker effect at higher doses. Functional outcomes — muscle, cognition, cardiovascular markers — have been mixed and modest where studied.
Fatigue and cognitive pilot studies
Small open-label and pilot studies of IV and subcutaneous NAD+ have reported improvements in subjective fatigue, focus, and mood. Study sizes are typically under 50 participants and most lack placebo controls, so the results are hypothesis-generating rather than definitive.
What research has not settled
The central open questions: (1) how much of injected or infused NAD+ reaches target tissues intact vs. being broken down peripherally; (2) whether raising blood NAD+ metabolites translates to meaningful clinical outcomes in humans; (3) optimal dosing and route; (4) long-term safety at supraphysiologic doses. Large, placebo-controlled, well-powered human trials remain limited.
Administration
NAD+ is administered by intravenous infusion or subcutaneous injection in therapeutic contexts. IV infusions are typically given in clinic settings and can range from 250 mg to 1,000+ mg per session, delivered over hours to tolerate the characteristic flushing and discomfort at higher rates. Subcutaneous injection protocols use smaller, more frequent doses and can be self-administered at home.
Because intact NAD+ is likely broken down peripherally, administration protocols are as much about pharmacokinetic strategy as they are about total dose. Research is ongoing into whether lower, more frequent dosing mimics the natural biosynthesis pattern more effectively than single high-dose infusions.
This is research context, not prescribing guidance. Your clinician will determine dosing and administration route based on your specific health profile and goals.
Side effects & safety considerations
Short-term safety of NAD+ administration has generally looked favorable in clinical reports, but long-term safety data at supraphysiologic doses is limited.
Common effects
During IV administration, patients commonly report chest tightness, flushing, nausea, and a feeling of pressure that resolves when the infusion rate is reduced. These effects are rate-dependent, not dose-dependent in a clinically dangerous sense. Subcutaneous injection typically produces injection-site reactions rather than systemic effects.
Theoretical and long-term concerns
Because NAD+-sirtuin signaling and PARP activity interact with pathways involved in cellular proliferation, there are theoretical concerns about administering high doses in people with active cancer or at high cancer risk. Most of these concerns are based on mechanistic reasoning rather than clinical observation; they are still appropriate cautions given limited long-term data.
Contraindications
- •Active malignancy or recent cancer history (relative contraindication; discuss with your clinician and oncology team)
- •Pregnancy or breastfeeding
- •Known sensitivity to nicotinamide or NAD+ compounds
- •Severe kidney or liver dysfunction may require dose adjustment
Your prescribing clinician will evaluate your medical history and health goals before determining whether NAD+ therapy is appropriate. This page is educational, not medical advice.
Regulatory context
Injectable and IV NAD+ is not FDA-approved for any indication. It is prepared on a patient- specific basis by licensed U.S. compounding pharmacies under the federal 503A framework. Some oral NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) are sold as dietary supplements; these are regulated differently and are not pharmaceutical products.
Because NAD+ therapy is off-label for nearly all use cases, patients and clinicians should be clear-eyed about the evidence base. The pharmacological rationale is strong and the mechanism is real, but proof of clinical benefit in humans at specific doses and routes is still accumulating.
The marketing narrative around NAD+ often runs ahead of the evidence, particularly on longevity and cognitive claims. Honest framing is central to how we talk about it.
Ready to see if NAD+ is right for you?
Take a 3-minute assessment. A licensed clinician reviews your health history and goals, then prescribes only if NAD+ therapy is clinically appropriate. Shipped from licensed U.S. compounding pharmacies.
Deep dives on NAD+
Research-backed articles covering specific topics in depth.
NAD+: How It Works & What to Expect
NAD+: Mechanistic explainer bridging NAD+ precursor science, aging hallmarks (sirtuins, PARP, mitochondrial function), and what current human trial data...
NAD+ Injections: How It Works & What to Expect
NAD+: Clinically grounded explainer covering NAD+ injection mechanisms, administration protocols, and candidate criteria — differentiating through medic...